ValuEngine Lowers AstraZeneca (NYSE:AZN) to Hold

AstraZeneca (NYSE:AZN) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.

A number of other research analysts have also commented on AZN. Pareto Securities upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, April 29th. Zacks Investment Research upgraded AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $45.29.

Shares of NYSE AZN traded up $0.59 during trading hours on Thursday, reaching $44.00. The stock had a trading volume of 2,686,100 shares, compared to its average volume of 4,559,933. The stock has a fifty day moving average price of $41.22. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $110.79 billion, a P/E ratio of 12.72, a price-to-earnings-growth ratio of 1.47 and a beta of 0.53. AstraZeneca has a twelve month low of $35.30 and a twelve month high of $44.74.

AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.43. The business had revenue of $5.72 billion during the quarter, compared to analyst estimates of $5.57 billion. AstraZeneca had a return on equity of 37.25% and a net margin of 9.38%. AstraZeneca’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 earnings per share. Research analysts predict that AstraZeneca will post 1.79 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. Cullen Frost Bankers Inc. lifted its stake in AstraZeneca by 3,392.8% in the second quarter. Cullen Frost Bankers Inc. now owns 226,508 shares of the company’s stock valued at $9,350,000 after buying an additional 220,023 shares during the period. Advisory Services Network LLC raised its position in shares of AstraZeneca by 5.6% during the second quarter. Advisory Services Network LLC now owns 6,373 shares of the company’s stock worth $263,000 after purchasing an additional 337 shares during the period. Keybank National Association OH raised its position in shares of AstraZeneca by 3.5% during the second quarter. Keybank National Association OH now owns 66,314 shares of the company’s stock worth $2,737,000 after purchasing an additional 2,249 shares during the period. Kornitzer Capital Management Inc. KS raised its position in shares of AstraZeneca by 29.3% during the second quarter. Kornitzer Capital Management Inc. KS now owns 56,100 shares of the company’s stock worth $2,316,000 after purchasing an additional 12,700 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of AstraZeneca by 0.7% during the second quarter. Janus Henderson Group PLC now owns 685,525 shares of the company’s stock worth $28,298,000 after purchasing an additional 4,751 shares during the period. Hedge funds and other institutional investors own 18.79% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: Portfolio Manager

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.